Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.
Eli Lilly: Don't Overthink This Buying Opportunity
Eli Lilly faced a 12% drop due to CVS formulary changes favoring Novo Nordisk, but I explain why this seems overstated. Lilly has gained control as the US market leader for GLP-1 drugs, and is still making steady gains as we speak. Lilly's strong US manufacturing expansion and Phase III study for Orforglipron augur well to maintain its leadership over Novo Nordisk.
Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Top 3 Stock Picks at the World's Greatest Hedge Fund
A reclusive firm is often considered the world's most successful hedge fund. That company is Renaissance Technologies.
Is Novo Nordisk Stock a Buy?
For years, Denmark-based Novo Nordisk (NVO -1.19%) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock exchanges, it didn't distinguish itself much in the vast sea that is the domestic biotech and pharmaceutical sectors.
Why Novo Nordisk Stock Popped Today
Novo Nordisk (NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m.
Novo Nordisk: The Fear Is Overblown
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk needs to grow in the mid-single digit range to justify the current valuation. Considering realistic growth rates, the company could be undervalued by 50+%.
Why Novo Nordisk Stock Is Soaring Today
Shares of Novo Nordisk (NVO 3.94%) are up on Tuesday. The company's stock gained 3.9% as of 2:40 p.m.
Growth Is Priced Out Of Novo Nordisk
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe the market has overshot to the downside. Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation.
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
Novo Nordisk (NVO) closed at $62.62 in the latest trading session, marking a +0.87% move from the prior day.
